Genomics company Illumina (NASDAQ: ILMN) reported Q3 2026 results topping the market’s revenue expectations, with sales up 7.6% year on year to $1.17 billion. The company’s full-year revenue guidance of $4.65 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.62 per share was 19.3% above analysts’ consensus estimates.
Is now the time to buy ILMN? Find out in our full research report (it’s free for active Edge members).
Illumina (ILMN) Q3 2026 highlights:
- Revenue $1.17 billion vs S&P analysts’ estimates of $1.15 billion (7.6% year-on-year growth, 1.1% beat)
- Adjusted EPS $1.62 vs S&P analysts’ estimates of $1.36 (19.3% beat)
- Adjusted operating income $292 million vs analyst estimates of $276.8 million (25% margin, 5.5% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $4.65 billion at the midpoint from $4.62 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $5.43 at the midpoint, a 1.4% increase
- Operating margin 26.2%, up from 20.9% in the same quarter last year
- Organic revenue rose 4.8% year on year (miss)
StockStory’s take
Illumina's third quarter was met with a negative market reaction, as revenues fell short of Wall Street's expectations despite year-over-year growth. Management attributed the quarter's performance to strong clinical sequencing demand and robust placements of the NovaSeq X platform, which CEO Jacob Thaysen described as fueling both margin and earnings expansion. However, the company acknowledged continued weakness in research and applied markets, offset by the momentum in clinical applications and new product introductions like the BioInsight software suite.
Looking ahead, Illumina’s updated guidance reflects management’s confidence in sustained clinical sequencing growth, expanded NovaSeq X adoption, and early traction in AI-driven initiatives such as the Billion Cell Atlas. CEO Jacob Thaysen highlighted opportunities arising from multi-omics and AI integration, emphasizing, “We are just getting started on the large AI-based predictive biology opportunity that lies ahead.” Management expects these developments to support revenue and margin expansion into next year.
Key insights from management’s remarks
Management cited high clinical sequencing demand, continued NovaSeq X placements, and new AI-powered solutions as the main drivers of recent financial performance and guidance updates.
- Clinical sequencing momentum: Clinical consumables grew strongly, driven by new diagnostic applications and elevated demand from large health systems. Management expects clinical to remain a key growth driver, citing double-digit growth rates in the U.S. and expanding international adoption.
- NovaSeq X platform expansion: Over 80 NovaSeq X instruments were placed in the quarter, with more than 360 units installed in the last year. The high-throughput X platform is displacing older models, leading to increased consumable usage and multi-year revenue streams.
- AI and data strategy progress: Illumina advanced its Billion Cell Atlas program, building large, standardized datasets to enable AI-driven drug discovery in partnership with biopharma clients like GSK. The BioInsight platform, integrating software and proprietary data, was launched to streamline analysis workflows and is expected to underpin future AI biology offerings.
- Research market stabilization: While research and applied sequencing consumables declined, management noted early signs of stabilization and anticipates a gradual recovery, especially as multi-omics and spatial biology applications gain traction.
- Operating margin improvement: Non-GAAP operating margins expanded, supported by disciplined spending and a favorable mix shift toward higher-margin clinical consumables. Management credited improved component pricing and logistics costs, while cautioning that further margin gains will depend on continued product mix improvement and scaling of new services.
Drivers of future performance
Illumina’s outlook is shaped by expectations for sustained clinical market growth, further NovaSeq X adoption, and scaling AI-enabled services.
- Clinical and multi-omics growth: Management anticipates ongoing double-digit growth in clinical sequencing, fueled by new diagnostic test launches and increasing demand for complex assays. Expansion in multi-omics, combining genomics with proteomics and transcriptomics, is expected to provide additional revenue streams, especially as research activity recovers.
- AI and data monetization: Revenue from large-scale datasets and related AI services, such as the Billion Cell Atlas and BioInsight platform, is projected to become more visible starting in 2027. Management believes these offerings could add one to two percentage points of growth as customers seek integrated analysis and predictive capabilities.
- Operational and margin risks: Although margins have improved, management cautions that future gains will rely on the successful mix shift toward higher-margin products and services, as well as stable component and shipping costs. Potential headwinds include pricing pressure from large customers, competitive dynamics, and regulatory uncertainties in key international markets.
Catalysts in upcoming quarters
In coming quarters, the StockStory team will closely watch (1) the pace of clinical sequencing growth, especially the adoption of new diagnostic tests and oncology applications; (2) further expansion and utilization of the NovaSeq X installed base, which underpins consumables revenue; and (3) progress in monetizing AI-driven data initiatives like the Billion Cell Atlas and BioInsight platform. Developments in China and regulatory outcomes will also be critical to track.
Illumina currently trades at $236.94, down from $290.06 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
